Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 51,231 shares at $39.44 ($2.0M) on 2021-10-15, disclosed to the SEC on 2021-10-18.
Open-market sale of $2.0M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.13 | 1,730 | $69K | 3.5% |
| 2 | $40.13 | 1,730 | $69K | 3.5% |
| 3 | $40.13 | 2,653 | $106K | 5.4% |
| 4 | $40.13 | 2,653 | $106K | 5.4% |
| 5 | $38.95 | 1,977 | $77K | 3.9% |
| 6 | $38.95 | 1,977 |
| $77K |
| 3.9% |
| 7 | $38.95 | 3,031 | $118K | 6.0% |
| 8 | $38.95 | 3,031 | $118K | 6.0% |
| 9 | $39.44 | 1,839 | $73K | 3.7% |
| 10 | $39.44 | 1,199 | $47K | 2.4% |
| 11 | $39.44 | 1,839 | $73K | 3.7% |
| 12 | $40.60 | 92 | $4K | 0.2% |
| 13 | $40.60 | 60 | $2K | 0.1% |
| 14 | $37.69 | 5,382 | $203K | 10.3% |
| 15 | $37.69 | 5,382 | $203K | 10.3% |
| 16 | $37.69 | 8,252 | $311K | 15.8% |
| 17 | $37.69 | 8,252 | $311K | 15.8% |
| 18 | $38.46 | 60 | $2K | 0.1% |
| 19 | $38.46 | 92 | $4K | 0.2% |
| Total | $38.53 avg | 51,231 | $2.0M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |